Everything below concerns animal model. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
The U.S. Army has commissioned ongoing research into potential risks of depleted uranium and other projectile weapon materials like tungsten, which the U.S. Navy has used in place of DU since 1993. Studies by the U.S. Armed Forces Radiobiology Research Institute conclude that moderate exposures to either depleted uranium or uranium present a significant toxicological threat. In 2003, Professor Brian Spratt FRS, chairman of the Royal Society's working group on depleted uranium, said: "The question of who carries out the initial monitoring and clean-up is a political rather than scientific question," and "the coalition needs to acknowledge that depleted uranium is a potential hazard and make in-roads into tackling it by being open about where and how much depleted uranium has been deployed." A 2008 review of all relevant articles appearing in the peer-reviewed journals on MEDLINE through to the end of 2007, including multiple cohort studies of veterans, found no consistent evidence of excess risks of neoplasms that could have some link to DU, and that "[t]he overall incidence of cancers is not increased in the cohort studies of Gulf war and Balkans veterans". One particular subgroup of veterans that may be at higher risk comprises those who have internally retained fragments of DU from shrapnel wounds.
=== Common === Empagliflozin increases the risk of genital fungal infections. The risk is highest in people with a prior history of genital fungal infections. Empagliflozin has been thought to be associated with increased risk of urinary tract infections. Reviews of clinical trials have shown there is no significant risk of developing urinary tract infections while taking empagliflozin when compared to placebo or other diabetic medications. Empagliflozin reduces systolic and diastolic blood pressure and can increase the risk of low blood pressure, which can cause fainting and/or falls. The risk is higher in older people, people taking diuretics, and people with reduced kidney function. Slight increases in Low-density lipoprotein (LDL) cholesterol can be seen with empagliflozin, in the range of 2–4% from baseline. Empagliflozin may cause a temporary decline in kidney function and, in rare cases, acute kidney injury, so it should be used cautiously in patients with kidney impairment. Some evidence suggests it may be safely used in people with significantly reduced kidney function (eGFR ≥ 20 mL/min/1.73 m2) while still providing renal benefits. However, given that this conclusion is largely based on a single major trial, further research is recommended to establish long-term safety and efficacy in this population.
== History == Cambrex was founded in 1979, when the Ennis Family acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. In 1990, Cambrex was listed on the NYSE. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco. Through multiple acquisitions during the late 1990s, the firm entered the bioscience and the chiral enzymatic catalyst markets. Cambrex acquired two contract biopharmaceutical manufacturing facilities in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, the firm decided to focus on its core competencies and sold the biologics business to Lonza Group. In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President. To broaden their biocatalysis platform, Cambrex acquired IEP in 2010, now known as Cambrex IEP. In 2019, Cambrex acquired Avista Pharma Solutions for $252m to become a fully integrated CDMO. In late 2019, Cambrex was acquired by an affiliate of the Permira funds. In 2020, Cambrex completed a major expansion at its Edinburgh, UK facility known for solid form screening alongside a biopharmaceutical expansion at its Durham, NC facility. Thomas Loewald was appointed CEO of Cambrex in September 2020. In 2022, Cambrex acquired Q1 Scientific, based out of Waterford, Ireland.
Sources: en.wikipedia.org
This organization, which had elected national officers and held an annual national meeting, was instrumental in gathering data from every Western-trained medical doctor in China, which was then published as William Hector Park compiled Opinions of Over 100 Physicians on the Use of Opium in China (Shanghai: American Presbyterian Mission Press, 1899). The vast majority of these medical doctors were missionaries; the survey also included doctors who were in private practices, particularly in Shanghai and Hong Kong, as well as Chinese who had been trained in medical schools in Western countries. In England, the home director of the China Inland Mission, Benjamin Broomhall, was an active opponent of the opium trade, writing two books to promote the banning of opium smoking: The Truth about Opium Smoking and The Chinese Opium Smoker. In 1888, Broomhall formed and became secretary of the Christian Union for the Severance of the British Empire with the Opium Traffic and editor of its periodical, National Righteousness. He lobbied the British Parliament to stop the opium trade. He and James Laidlaw Maxwell appealed to the London Missionary Conference of 1888 and the Edinburgh Missionary Conference of 1910 to condemn the continuation of the trade. When Broomhall was dying, his son Marshall read to him from The Times the welcome news that an agreement had been signed ensuring the end of the opium trade within two years.
Carol Beattie is appointed chief executive of the Scottish National Party after taking on the post in an acting role following the resignation of her predecessor, Murray Foote. 11 March – The Metropolitan Police launch an investigation into Rupert Lowe over allegations of making "verbal threats". The Democracy and Boundary Commission has decided that all Senedd seats will have Welsh language only names from 2026. Reform UK gains its first representative on Falkirk Council following the defection of ex-Conservative turned Independent councillor Claire Mackie-Brown. 12 March – Keir Starmer says the UK will "keep all options on the table" regarding Donald Trump's steel and aluminium tariffs. All 404 Labour MPs are summoned to Downing Street for a briefing on the spring statement. Former First Minister of Scotland, Nicola Sturgeon, announces she will stand down from the Scottish Parliament at the 2026 election. Health Secretary Wes Streeting calls for his former assistant Sam Gould to resign from Redbridge London Borough Council after he admitted to indecent exposure. The requirement for a High Court judge to approve applications is dropped by the bill committee of the Terminally Ill Adults (End of Life) Bill. South Kesteven councillor Rosemary Trollope-Bellew leaves Reform UK just 11 days after joining. 13 March – Keir Starmer announces that NHS England will be abolished in order to "cut bureaucracy". First Minister of Scotland John Swinney holds talks with Eric Trump, the son of US President Donald Trump, at Bute House.
==== 2010-2019 ==== On March 18, 2010, Teva said it planned to acquire German generic Ratiopharm for US$5 billion. The deal was completed in August 2010, significantly expanding Teva's European coverage. In May 2011, Teva bought Cephalon for US$6.8 billion. The same month, Teva announced the ¥40 billion purchase of a majority stake in Japanese generic drug company Taiyo Pharmaceutical Industry, a move to secure a Japan-local production facility. Teva completed the $934 million acquisition in July 2011. In June 2013, Teva acquired US firm MicroDose Therapeutx for $40 million with as much as $125 million being paid in regulatory and developmental milestones In 2010, Teva announced that it would build its main distribution center for the Americas in Philadelphia, PA, and was considering opening its US headquarters in the area. In 2010, it had 39,660 employees. In Israel, the number of workers rose 7.5% by 6,774. In October 2010, Teva entered a licensing agreement with BioTime to develop and market BioTime's OpRegen for the treatment of age-related macular degeneration, an effort that in 2013 received $1.5 billion in funding from Israel's Office of the Chief Scientist. In May 2011, Teva announced it would purchase Cephalon for US$6.8 billion. In January 2014, Teva acquired NuPathe, after outbidding Endo, for $144 million. In June 2014, Teva acquired Labrys Biologics for up to $825 million, the aim being to strengthen the company's migraine pipeline through addition of LBR-101, an anti-CGRP monoclonal antibody therapeutic.
Sources: en.wikipedia.org
== Chemical synthesis == Ipglycermides are readily synthesized using automated solid phase peptide synthesis and incorporate the thioether macrocycle linkage via cyclization achieved between a free cysteine thiol and N-chloroacetyl containing tyrosine.
(People with HIV/AIDS or hepatitis C are usually excluded from this requirement.) In practice, 40–65% of patients maintain abstinence from additional opioids while receiving opioid replacement therapy and 70–95% can reduce their use significantly. Medical (improper diluents, non-sterile injecting equipment), psychosocial (mental health, relationships), and legal (arrest and imprisonment) issues that can arise from the use of illegal opioids are concurrently eliminated or reduced. Clonidine or lofexidine can help treat the symptoms of withdrawal. The period when initiating methadone and the time immediately after discontinuing treatment with both drugs are periods of particularly increased mortality risk, which should be dealt with by both public health and clinical strategies. ORT has proved to be the most effective treatment for improving the health and living condition of people experiencing illegal opiate use or dependence, including mortality reduction and overall societal costs, such as the economic loss from drug-related crime and healthcare expenditure. A review of UK hospital policies found that local guidelines delayed access to substitute opioids, for instance by requiring lab tests to demonstrate recent use or input from specialist drug teams before prescribing. Delays to access can increase people's risk of discharging themselves early against medical advice.
MVA-BN (brand names: Imvanex, Imvamune, and Jynneos) is a modified vaccinia Ankara (MVA) vaccine manufactured by Bavarian Nordic by growing MVA in cell culture. Unlike replicating vaccines, MVA-BN is administered by injection via the subcutaneous route and does not result in a vaccine "take." A "take" or "major cutaneous reaction" is a pustular lesion or an area of definite induration or congestion surrounding a central lesion, which can be a scab or an ulcer. MVA-BN can also be administered intradermally to increase the number of available doses. It is safer for immunocompromised patients and those who are at risk from a vaccinia infection. MVA-BN has been approved in the European Union, Canada, and the United States. Clinical trials have found that MVA-BN is safer and just as immunogenic as ACAM2000. This vaccine has also been approved for use against mpox. It received WHO prequalification against smallpox and Mpox in September 2024.
In addition, the Times reported that Vice President-elect JD Vance had led a group of Republicans, including Donald Trump Jr., former Trump aide Steve Bannon, political activist Charlie Kirk, and Breitbart News reporter Matt Boyle, to support Hegseth's nomination. Trump allies took a direct approach to addressing the controversies, including an interview with Megyn Kelly that impressed Trump. Hegseth appeared at the United States Capitol in December; Trump publicly reaffirmed his support for Hegseth afterwards. The visit gave Iowa senator Joni Ernst, who had threatened his nomination, a positive impression of Hegseth. Hegseth appeared before the Senate Committee on Armed Services on January 14. He positioned himself as a "warrior" while denying the allegations and his previous claims that women should not serve in combat roles. Hegseth was criticized by Democrats over allegations of sexual misconduct, financial mismanagement, and alcohol issues. Rhode Island senator Jack Reed, the committee's ranking member, noted that Hegseth had used the term "jagoff" in his book The War on Warriors (2024) to derogatorily refer to a Judge Advocate General officer who reprimanded him on the use of rocket-propelled grenades. He did not answer a question from Virginia senator Tim Kaine on whether or not sexual assault, drinking, or infidelity were disqualifying. The Committee on Armed Services voted to advance his nomination 14–13 along party lines on January 20, after Trump was inaugurated.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.